News
Jan 13, 2026:
Instanosis published a new lateral flow technique on ACS Applied Bio Materials. The new technique allows the quantitative detection of analytes across a broad concentration range without an external instrument. Importantly, the new technique is not subject to the Hook Effect which avoids false negative reading. To learn more, read the full article at ACS publications:
Jan 8, 2026:
Instanosis 3-in-1 drug test strips are now available in vending machine!
Jul 23, 2025:
Instanosis Wins Prestigious Award for Breakthrough Xylazine Detection Technology
Feb 14, 2025:
An independent evaluation of Instanosis Xylazine test strip was published by CFSRE
https://www.cfsre.org/nps-discovery/drug-checking/evaluation-of-instanosis-xylazine-test-strips
In parallel, CFSRE also evaluated another strip
The result showed that Instanosis Xylazine strip is 200x more sensitive and 100% specific.
Oct 14, 2024:
Instanosis was selected as a company in NIH Innovation Pavilion at the MedTech Conference.
July 30 – Aug 1, 2024:
Instanosis exhibited at the Association for Diagnostics & Laboratory Medicine (ADLM) 2024 Clinical Lab Expo from July 30th to August 1st in Chicago, IL. ADLM is a global conference which hosts leaders in clinical chemistry, molecular diagnostics, and other areas of breaking science in laboratory medicine.
May 17, 2024:
Instanosis published a new research paper on a novel chemiluminescence assay for the rapid and sensitive detection of fentanyl. The work is done through a multi-institutional collaboration including Instanosis Inc., the University of Pennsylvania, Mayo Clinic, and ATGC Inc.
April 15, 2024:
Instanosis announces the FDA clearance of InstaStrip Fentanyl. The product is a dipstick test for the qualitative detection of Fentanyl in human urine. InstaStrip Fentanyl is both CLIA-Waived and OTC compliant. The kit detect Fentanyl in human urine at a cutoff of 1 ng/mL.
March 18, 2024:
Instanosis has been awarded a new NIH Blue Print Medtech Small Business Translator SBIR grant for developing a rapid urine xylazine test device.
March 18, 2024:
Instanosis has been awarded a new NIH fast track SBIR grant for developing a rapid urine fentanyl test device.
October 24, 2023:
Instanosis’s InstaStrip-Fentanyl Rapid Test has been granted Breakthrough Device designation by the United States Food and Drug Administration (FDA).
June 20, 2023:
Instanosis has successfully implemented Quality Management System, compliant with FDA requirements
June 16, 2023:
Instanosis is awarded a Small Business Innovation Research grant supplement from the NIH to develop lateral flow assays for rapid fentanyl detection
June 06, 2023:
Instanosis is awarded a Small Business Technology Transfer Grant from the NIH to use smartphones to reduce prostate cancer monitoring disparities
August 22, 2022:
Instanosis is awarded a Small Business Innovation Research Grant from the NIH to develop lateral flow assays for rapid fentanyl detection